Seraxis
PrivateLast Round
Convertible Debt
Sep 24, 2026
Total Funding Raised
$58.62M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Seraxis operates in Healthcare & Life Sciences and is based in Germantown, Maryland. Its latest recorded funding round was a Grant round in May 2025.
Seraxis is a biotechnology company that develops cell replacement therapies to provide a long-term cure for insulin-dependent diabetes by producing insulin to regulate glucose levels without requiring immune suppression.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Seraxis Comparables
Compare Seraxis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Encellin | 84% | |
| Kadimastem Ltd. | 84% | |
| Sernova Biotherapeutics Inc. | 84% |
For institutional investors. Book with your work email.
Seraxis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Sep 24, 2026 | ||||
| Grant | May 13, 2025 | ||||
| Grant | May 14, 2024 | ||||
| Series C Extension | Sep 21, 2023 | ||||
| Series C | Feb 9, 2021 | ||||
Grant | May 11, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Seraxis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Frazier Healthcare Partners | Series C |
| ASAP Ventures | Series A |
| Frazier Life Sciences | Series C, Series C Extension |
| East West Capital Partners | Series A |
| JDRF | Series C, Series C Extension |
| GRI Fund | Series A |
| Maryland Stem Cell Research Fund | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 5, 2026
$10M raised in Seed Round.
- Aug 21, 2026
Monthly visitors increased 120% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 22, 2026
Seraxis appoints Patricia Beaston, M.D., Ph.D., as Chief Medical Officer as it prepares to initiate a Phase 1/2 trial of SR-02 for type 1 diabetes.
- receives_financingOct 5, 2026
On Oct 5th '26, Seraxis receives $11.2M in convertible note financing from insiders, management, existing shareholders, and new investors to support its proposed merger and advance a type 1 diabetes cell therapy toward a Phase 1/2 clinical trial.
- attends_eventSep 25, 2026
Seraxis is scheduled to participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference alongside Sernova Biotherapeutics on Oct 1st '26 at 1:30 p.m. Eastern Time, with a joint presentation and fireside-style Q&A.
- acquiresSep 11, 2026
On Sep 11th '26, Seraxis proposes to acquire all securities of Sernova Corp. under an arrangement agreement dated Sep 7th '26, with shareholders exchanging their shares for Seraxis shares.
For institutional investors. Book with your work email.
Seraxis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Seraxis's valuation, stock price, and market status.
Is Seraxis a public or private company?
Seraxis is a private company.
What is the current stock price of Seraxis?
Seraxis is a private company, so its shares have no public market price. Caplight tracks Seraxis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Seraxis worth (valuation)?
Valuation information for Seraxis is not publicly available.
Can I buy Seraxis stock?
Seraxis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Seraxis's last funding round?
Seraxis's most recent funding round was Convertible Debt on September 24, 2026.
Who are the main investors in Seraxis?
Key investors in Seraxis include East West Capital Partners, Maryland Stem Cell Research Fund.
Will Seraxis IPO soon?
No public IPO plans have been announced for Seraxis.
How can I track Seraxis secondary market activity?
Caplight tracks bids, offers, and trades in Seraxis's shares on secondary markets.